Long noncoding RNAs and their role in multiple myeloma treatment
Project 3: Defining the biologic role and therapeutic implications of lncRNA in multiple myeloma
Researchers are looking at how long noncoding RNAs affect myeloma cells to find new treatment targets for people with multiple myeloma.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11179323 on NIH RePORTER |
What this research studies
This project maps long noncoding RNAs (lncRNAs) in multiple myeloma and in the bone marrow environment to understand how they control gene activity and disease behavior. The team combines genome-wide and epigenetic analyses with laboratory experiments in cell and animal models and with data from patient samples. They test whether changing these lncRNA networks alters myeloma growth, survival, or resistance to drugs. The goal is to identify biomarkers or molecular targets that could inform future therapies or clinical trials.
Who could benefit from this research
Good fit: People diagnosed with multiple myeloma, particularly those willing to provide bone marrow or tumor samples or to enroll in future related trials, would be the ideal candidates.
Not a fit: People without multiple myeloma, or those seeking an immediate change to their current treatment, are unlikely to receive direct benefit from this primarily lab-focused research.
Why it matters
Potential benefit: If successful, this work could reveal new drug targets or biomarkers that lead to more effective or personalized treatments for people with multiple myeloma.
How similar studies have performed: Prior research has linked lncRNA patterns to myeloma prognosis, but converting those findings into safe, effective therapies is still largely experimental.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Anderson, Kenneth C. — Dana-Farber Cancer Inst
- Study coordinator: Anderson, Kenneth C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.